Genomic Surveillance for SARS-CoV-2 — China, September 26, 2022 to January 29, 2023
Shiwen Wang(Chinese Center For Disease Control and Prevention), Wenbo Xu(Shenyang Institute of Automation), Qiudong Su(National Institute for Viral Disease Control and Prevention), Zhixiao Chen(National Institute for Viral Disease Control and Prevention), Cao Chen(Nanjing Medical University), Caiyun Long(National Institute for Viral Disease Control and Prevention), Zhongxian Zhang(Zhengzhou University), Changcheng Wu(Chinese Center For Disease Control and Prevention), Yuchao Wu(National Institute for Viral Disease Control and Prevention), Peihua Niu(National Institute for Viral Disease Control and Prevention), Xiaoyu Yang(National Institute for Viral Disease Control and Prevention), Yenan Feng(National Institute for Viral Disease Control and Prevention), Xiang Zhao(Guangdong Polytechnic Normal University), Jing Tang(National Institute for Viral Disease Control and Prevention), Lili Li(Northwest A&F University), Ji Wang(Zhejiang Lab), Yan Zhang(Fujian Medical University), Xiaozhou He(The First People's Hospital of Changzhou), Hong Bo(National Institute for Viral Disease Control and Prevention), Ai‐Li Cui(Sichuan University), Wenling Wang(National Institute for Viral Disease Control and Prevention), Zeyuan Yin(National Institute for Viral Disease Control and Prevention)
Cited by 43
Related Papers
A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k